The BDX-XL2 test has shown early promise in ruling out cancer through blood samples.
A 1,048-patient study published in the Oncologist demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer.
Methods for measuring ctDNA, circulating tumour RNA (ctRNA), and circulating proteomic signatures from the blood are non-invasive and provide diagnostic information.
In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.
Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.
Can prognostic testing improve care for lung cancer patients and help physicians meet OCM quality measures? Dr. Ray Page discusses the topic.
Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.
Article from Global Engage, interviewing Dr. Gary Pestano and Dr. Hestia Mellert about the future of droplet digital PCR.
Clinical lab products article: Blood-Based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry. Comments from Dr. Pritchett, Dr. Niu
Increasingly, medical oncologists work with multidisciplinary teams to diagnose and manage lung cancer cases.